Discover
DRTS
Alpha Tau Medical Ltd.
14.53
1 x 14.68
2 x 18.50
bid
ask
-
0.11
0.75%
10:25 AM
timesize
| Ytd | 193.54% | |
| 1y | 324.85% |
14.41
day range
15.00
3.35
52 week range
15.10
| Open | 14.68 | Prev Close | 14.64 | Low | 14.41 | High | 15.00 | Mkt Cap | 1.34B |
| Vol | 130.79K | Avg Vol | 748.20K | EPS | -1.04 | P/E | N/A | Forward P/E | -27.79 |
| Beta | 1.17 | Short Ratio | 5.25 | Inst. Own | 8.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-19 | 50-d Avg | 12.87 | 200-d Avg | 8.52 | 1yr Est | 14.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-19 | 2026-09 | -0.14 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.14 | -0.5 | -0.36 | -254.91% |
| 2026-05-18 | 2026-03 | -0.13 | -0.26 | -0.13 | -100.00% |
| 2026-03-09 | 2025-12 | -0.13 | -0.14 | -0.01 | -7.69% |
| 2025-11-20 | 2025-09 | -0.12 | -0.14 | -0.02 | -16.67% |
| 2025-08-11 | 2025-06 | -0.12 | -0.13 | -0.01 | -8.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | Barclays | Upgrade | Overweight | Overweight |
| 2026-06-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-20 | LEVY RAPHI | Chief Financial Officer | 90.18K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Gem Investment Advisors, LLC | 1.43M | 21.00M | 2.07% |
| 2026-06-29 | HighTower Advisors, LLC | 874.99K | 12.81M | 1.26% |
| 2026-06-29 | Boothbay Fund Management, LLC | 773.48K | 11.32M | 1.12% |
| 2026-06-29 | Aquamarine Financial (cayman) Ltd | 721.50K | 10.56M | 1.04% |
| 2026-06-29 | Pier Capital, LLC | 691.94K | 10.13M | 1.00% |
| 2026-06-29 | UBS Group AG | 642.26K | 9.40M | 0.93% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-07-30 | ARK ETF Trust-ARK Israel Innovative Technology ETF | 184.38K | 2.70M | 0.27% |
| 2026-07-30 | RBB Fund, Inc.-Adara Smaller Companies Fund | 129.36K | 1.89M | 0.19% |
| 2026-06-29 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 53.40K | 781.76K | 0.08% |
| 2026-03-30 | Tidal Trust II-Even Herd Long Short ETF | 25.09K | 367.36K | 0.04% |
| 2026-04-29 | Dunham Funds-Dunham Small Cap Growth Fund | 27.11K | 396.91K | 0.04% |
| 2026-06-29 | 360 Funds-Timber Point Global Allocations Fund | 20.00K | 292.80K | 0.03% |